Cormedix INC 8-K filings

CorMedix Therapeutics announced robust second quarter 2026 financial results, including $101.9 million in consolidated revenue and $26.0 million in net income, while raising its full-year adjusted EBITDA guidance.

CorMedix Inc. announces preliminary approval of a settlement for consolidated shareholder derivative lawsuits, resolving claims through corporate governance reforms.

CorMedix Inc. announced a change in its independent registered public accounting firm, dismissing CBIZ CPAs P.C. and appointing Ernst & Young LLP.

CorMedix announced a significant legal victory as the U.S. Court of Appeals for the Federal Circuit affirmed a lower court's decision, ruling that Nexus Pharmaceuticals' generic minocycline product infringes CorMedix's patents.

CorMedix Therapeutics announced robust first quarter 2026 financial results, exceeding expectations with significant revenue and net income growth, and consequently raising its full-year financial guidance.

CorMedix Therapeutics reports positive topline results from its Phase III ReSPECT trial for REZZAYO (rezafungin) in preventing invasive fungal diseases in stem cell transplant patients, meeting its primary endpoint.

CorMedix Inc. reaffirmed its full-year 2027 DefenCath sales guidance of $100 million to $140 million, correcting a prior earnings call statement, and highlighted a diversified product portfolio and pipeline growth opportunities.

CorMedix Inc. announced robust financial results for the fourth quarter and full year ended December 31, 2025, driven by DefenCath sales and the Melinta acquisition.

CorMedix Therapeutics announced strong preliminary Q4 and FY 2025 results, elevated CEO Joseph Todisco to Chairman, and appointed a new Chief Commercial Officer, but cautioned on a significant DefenCath reimbursement decline in H2 2026.

CorMedix Inc. reported strong third-quarter 2025 financial results, driven by DefenCath sales and the Melinta acquisition, leading to raised full-year guidance.

CorMedix Inc. announced strong preliminary third-quarter 2025 financial results and increased its full-year 2025 pro forma net revenue guidance to at least $375 million, driven by robust DefenCath sales and Melinta portfolio performance.

CorMedix Inc. completed its acquisition of Melinta Therapeutics, LLC, disclosing pro forma financial statements and details of the $300 million cash and stock deal.

CorMedix Inc. has finalized its acquisition of Melinta Therapeutics, expanding its product portfolio, appointing new executives, and projecting significant revenue growth and synergies.

CorMedix Inc. has completed a $150 million private placement of 4.00% convertible senior notes due 2030, enhancing its financial flexibility.

CorMedix Inc. announced a definitive agreement to acquire Melinta Therapeutics, LLC for $300 million upfront, significantly expanding its commercial product portfolio and projecting substantial revenue and EBITDA growth.

CorMedix Inc. has successfully closed its public offering of common stock, raising approximately $82.2 million in net proceeds, with potential for an additional $12.6 million if underwriters exercise their option in full, to support its strategic initiatives and product development.

CorMedix Inc. announced that its stockholders re-elected all seven director nominees, approved executive compensation on an advisory basis, and ratified the appointment of CBIZ CPAs P.C. as its independent registered public accounting firm for 2025 at the 2025 Annual Meeting.

CorMedix Inc. announced an expanded implementation of its lead product, DefenCath, with a Large Dialysis Organization customer, leading to an upward revision of its second-quarter net sales guidance.

CorMedix announces a profitable first quarter in 2025 with net revenue of $39.1 million and adjusted EBITDA of $23.6 million, driven by successful DefenCath implementation.

CorMedix Inc. announces the resignation of Marcum LLP as its independent registered public accounting firm and the engagement of CBIZ CPAs P.C., effective April 17, 2025.

CorMedix reports robust preliminary Q1 2025 results, including $39.0 million in net revenue and raises its H1 2025 net sales guidance to $62-$70 million.

CorMedix announces its first profitable commercial quarter in history, driven by strong DefenCath sales, with net revenue of $31.2 million for Q4 2024.

CorMedix reports preliminary Q4 2024 revenue of approximately $31 million and expects adjusted EBITDA to exceed $12 million, alongside an expansion into the inpatient hospital segment.

CorMedix Inc. stockholders approved an amendment to the company's stock incentive plan and elected directors at their annual meeting held on November 21, 2024.

CorMedix reports its first full quarter of DefenCath sales, achieving $11.5 million in net revenue and securing agreements with major dialysis providers.

CorMedix announced its second quarter and six-month 2024 financial results, highlighted by the initial sales of DefenCath and progress in expanding its commercial reach.

CorMedix announced its first quarter 2024 financial results, highlighted by the commercial launch of DefenCath and progress towards outpatient availability.

CorMedix announced its fourth quarter and full year 2023 financial results, highlighted by the FDA approval of DefenCath and preparations for its commercial launch.

CorMedix has received a positive reimbursement determination from CMS for DefenCath, setting the stage for its commercial launch with inpatient availability targeted for April 15, 2024, and outpatient availability targeted for July 1, 2024.